Alto Neuroscience, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Alto Neuroscience, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $75.00K.
- Alto Neuroscience, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $6.00K, a 96.97% decline year-over-year.
- Alto Neuroscience, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $154.00K, a 129.85% increase year-over-year.
- Alto Neuroscience, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $198.00K, a 1880.00% increase year-over-year.
- Alto Neuroscience, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $707.00K, a 278.07% increase from fiscal 2024.
- Alto Neuroscience, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $187.00K, a 3.31% increase from fiscal 2023.
- Alto Neuroscience, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $181.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $75.00K 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $6.00K 10-Q · filed 2026-08-12 | |
| 2025-12-31 | $707.00K 10-K · filed 2026-03-16 | |
| 2025-09-30 | $154.00K 10-Q · filed 2025-11-12 | |
| 2025-03-31 | $198.00K 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $187.00K 10-K · filed 2026-03-16 | |
| 2024-09-30 | $67.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $61.00K 10-Q · filed 2025-11-12 | |
| 2024-03-31 | $10.00K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $181.00K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $109.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $43.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |